Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
South Korea · Delayed Price · Currency is KRW 72,600
-1,400 (-1.89%)
Sep 10, 2026, 9:15 AM KST
Mezzion Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,428 | 7,910 | 8,612 | 31,721 | 30,726 | 26,654 |
Other Revenue | - | - | - | -0 | - | - |
| 8,428 | 7,910 | 8,612 | 31,721 | 30,726 | 26,654 | |
Revenue Growth | 6.93% | -8.15% | -72.85% | 3.24% | 15.28% | -6.92% |
Cost of Revenue | 6,994 | 6,529 | 6,701 | 27,836 | 31,040 | 22,956 |
Gross Profit | 1,435 | 1,381 | 1,910 | 3,884 | -313.44 | 3,698 |
Selling, General & Admin | 18,170 | 15,973 | 14,958 | 16,142 | 19,510 | 17,283 |
Research & Development | 1,260 | 1,260 | 294.04 | 938.97 | 2,217 | 1,956 |
Operating Expenses | 20,313 | 18,221 | 16,210 | 18,373 | 23,018 | 20,496 |
Operating Income | -18,878 | -16,840 | -14,300 | -14,489 | -23,331 | -16,798 |
Interest Expense | -3,205 | -1,572 | -300.79 | -315.46 | -423.44 | -323.41 |
Interest & Investment Income | 700.06 | 621.96 | 1,431 | 1,477 | 763.35 | 306.23 |
Currency Exchange Gain (Loss) | -55.26 | -71.67 | 286.56 | 996.94 | 3,177 | 3,700 |
Other Non Operating Income (Expenses) | -4,617 | -21,020 | -1,180 | -157.21 | -1,410 | 90.67 |
EBT Excluding Unusual Items | -26,056 | -38,882 | -14,062 | -12,488 | -21,225 | -13,025 |
Gain (Loss) on Sale of Assets | 55.95 | 44.05 | -471.69 | 7.35 | 8.99 | -1.08 |
Asset Writedown | - | - | - | - | -14,694 | - |
Other Unusual Items | -3,343 | - | - | - | - | - |
Pretax Income | -29,342 | -38,838 | -14,534 | -12,480 | -35,910 | -13,026 |
Income Tax Expense | -1,950 | -3,909 | 4,943 | 248.07 | 388.23 | 577.06 |
Earnings From Continuing Operations | -27,392 | -34,929 | -19,477 | -12,728 | -36,298 | -13,603 |
Net Income | -27,392 | -34,929 | -19,477 | -12,728 | -36,298 | -13,603 |
Net Income to Common | -27,392 | -34,929 | -19,477 | -12,728 | -36,298 | -13,603 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 30 | 30 | 30 | 28 | 27 | 27 |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 28 | 27 | 27 |
Shares Change | 1.36% | 0.98% | 5.62% | 5.63% | 0.17% | 2.63% |
EPS (Basic) | -902.06 | -1159.66 | -653.00 | -450.74 | -1357.81 | -509.70 |
EPS (Diluted) | -902.06 | -1159.66 | -653.00 | -451.00 | -1358.00 | -510.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -20,550 | -16,725 | -19,080 | -11,553 | -12,842 | -15,429 |
Free Cash Flow Per Share | -676.75 | -555.29 | -639.69 | -409.10 | -480.39 | -578.14 |
Gross Margin | 17.02% | 17.46% | 22.18% | 12.25% | -1.02% | 13.88% |
Operating Margin | -223.98% | -212.91% | -166.05% | -45.67% | -75.93% | -63.02% |
Profit Margin | -324.99% | -441.61% | -226.17% | -40.13% | -118.13% | -51.03% |
Free Cash Flow Margin | -243.82% | -211.46% | -221.56% | -36.42% | -41.80% | -57.89% |
EBITDA | -17,995 | -15,852 | -13,342 | -12,942 | -21,673 | -15,212 |
EBITDA Margin | -213.50% | -200.42% | -154.93% | -40.80% | -70.54% | -57.07% |
D&A For EBITDA | 882.91 | 988.12 | 957.8 | 1,546 | 1,658 | 1,586 |
EBIT | -18,878 | -16,840 | -14,300 | -14,489 | -23,331 | -16,798 |
EBIT Margin | -223.98% | -212.91% | -166.05% | -45.67% | -75.93% | -63.02% |